Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis

dc.contributor.authorde Ruiter, Michiel B.
dc.contributor.authorDeardorff, Rachael L.
dc.contributor.authorBlommaert, Jeroen
dc.contributor.authorChen, Bihong T.
dc.contributor.authorDumas, Julie A.
dc.contributor.authorSchagen, Sanne B.
dc.contributor.authorSunaert, Stefan
dc.contributor.authorWang, Lei
dc.contributor.authorCimprich, Bernadine
dc.contributor.authorPeltier, Scott
dc.contributor.authorDittus, Kim
dc.contributor.authorNewhouse, Paul A.
dc.contributor.authorSilverman, Daniel H.
dc.contributor.authorSchroyen, Gwen
dc.contributor.authorDeprez, Sabine
dc.contributor.authorSaykin, Andrew J.
dc.contributor.authorMcDonald, Brenna C.
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2024-11-19T12:49:33Z
dc.date.available2024-11-19T12:49:33Z
dc.date.issued2023
dc.description.abstractBrain gray matter (GM) reductions have been reported after breast cancer chemotherapy, typically in small and/or cross-sectional cohorts, most commonly using voxel-based morphometry (VBM). There has been little examination of approaches such as deformation-based morphometry (DBM), machine-learning-based brain aging metrics, or the relationship of clinical and demographic risk factors to GM reduction. This international data pooling study begins to address these questions. Participants included breast cancer patients treated with (CT+, n = 183) and without (CT-, n = 155) chemotherapy and noncancer controls (NC, n = 145), scanned pre- and post-chemotherapy or comparable intervals. VBM and DBM examined GM volume. Estimated brain aging was compared to chronological aging. Correlation analyses examined associations between VBM, DBM, and brain age, and between neuroimaging outcomes, baseline age, and time since chemotherapy completion. CT+ showed longitudinal GM volume reductions, primarily in frontal regions, with a broader spatial extent on DBM than VBM. CT- showed smaller clusters of GM reduction using both methods. Predicted brain aging was significantly greater in CT+ than NC, and older baseline age correlated with greater brain aging. Time since chemotherapy negatively correlated with brain aging and annual GM loss. This large-scale data pooling analysis confirmed findings of frontal lobe GM reduction after breast cancer chemotherapy. Milder changes were evident in patients not receiving chemotherapy. CT+ also demonstrated premature brain aging relative to NC, particularly at older age, but showed evidence for at least partial GM recovery over time. When validated in future studies, such knowledge could assist in weighing the risks and benefits of treatment strategies.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationde Ruiter MB, Deardorff RL, Blommaert J, et al. Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis. Brain Imaging Behav. 2023;17(5):507-518. doi:10.1007/s11682-023-00781-7
dc.identifier.urihttps://hdl.handle.net/1805/44627
dc.language.isoen_US
dc.publisherSpringer
dc.relation.isversionof10.1007/s11682-023-00781-7
dc.relation.journalBrain Imaging and Behavior
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectBrain aging
dc.subjectBreast cancer
dc.subjectChemotherapy
dc.subjectGray matter
dc.subjectMagnetic resonance imaging (MRI)
dc.titleBrain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
deRuiter2023Brain-AAM.pdf
Size:
482.24 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: